The projection of FY24 revenue by Codexis, especially the specific exclusion of PAXLOVID revenue, indicates a clear financial outlook for the company. This detailed forecast could positively influence investor sentiment by providing clarity on expected revenue streams, excluding the potentially volatile PAXLOVID-related revenue. The anticipation of solid product and R&D revenue suggests a stable growth trajectory, likely leading to a positive short-term impact on CDXS's stock price.